Santhera to Present Data and Host Symposium on Pulmonary Function in Duchenne Muscular Dystrophy at the American Thoracic Society 113th Annual Conference

Liestal, Switzerland, May 16, 2017 – Santhera Pharmaceuticals, a specialty pharmaceutical company focused on the development of innovative treatments for rare mitochondrial and neuromuscular diseases, announces that two posters with data from the positive phase III DELOS trial in patients with Duchenne muscular dystrophy (DMD) will be presented at the 113th American Thoracic Society (ATS) International Conference in Washington D.C.